Analysts/Institutional Investor Meet/Con. Call UpdatesNSE filing · raw filing ↗
14 Aug 2026
⚑ Filing
Orchid Pharma Ltd - 524372 - Statement Of Deviation Or Variation For The Quarter Ended June 30, 2026 On The Use Of Proceeds Of Funds Raised Through Qualified Institutional PlacementBSE filing · raw filing ↗
14 Aug 2026
⚑ Filing
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Monitoring Agency ReportBSE filing · raw filing ↗
14 Aug 2026
⚑ Result
Orchid Pharma Ltd - 524372 - Outcome Of Board Meeting Held For Considering And Approving Revised Audited Financial Results For The Year Ended March 31, 2026 Pursuant To Scheme Of Merger.BSE filing · raw filing ↗
Orchid Pharma Ltd - 524372 - Financial Results For Quarter-1 Of F.Y. 2026-27 Ended June 30, 2026.BSE filing · raw filing ↗
14 Aug 2026
⚑ Filing
Orchid Pharma Ltd - 524372 - Board Meeting Outcome for Outcome Of Board MeetingBSE filing · raw filing ↗
14 Aug 2026
⚑ Filing
Q1 FY27 results filed — revenue ₹304 Cr (+75.9% YoY), PAT ₹3 Cr (−78.4% YoY)NSE filing · raw filing ↗
11 Aug 2026
⚑ Filing
Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 14, 2026.BSE filing · raw filing ↗
Statement of deviation(s) or variation(s) under Reg. 32NSE filing · raw filing ↗
25 May 2026
⚑ Filing
Q4 FY26 results filed — revenue ₹238 Cr (+0.1% YoY), PAT ₹24 Cr (+6.7% YoY)NSE filing · raw filing ↗
19 May 2026
⚑ Filing
Analysts/Institutional Investor Meet/Con. Call UpdatesNSE filing · raw filing ↗
NOT BUILT YETPer-item summaries & sentiment — not built yetOne-line plain-language summaries and a sentiment read of every filing. Not built yet. When they exist they will describe — never advise.
Official filings & corporate actions · newest first
